Antiverse, a UK-based biotech firm, has successfully raised $9.3 million in a Series A funding round, spearheaded by Soulmates Ventures. This round included contributions from Innovation Investment Capital, DOMiNO Ventures, and existing investors such as DBW, Kadmos Capital, and i&i Biotech Fund. With this latest financing, Antiverse’s total capital raised now exceeds $20 million.
Challenges in Drug Discovery
Modern medicine faces significant hurdles in treating diseases associated with so-called undruggable molecular targets. This category includes complex proteins that have historically resisted therapeutic intervention. The drug discovery process in this challenging landscape is fraught with difficulty, highlighted by an alarming attrition rate of around 90% for candidates that progress to clinical trials.
Antiverse’s Innovative Approach
Antiverse is addressing these obstacles through an AI-driven computational platform specifically designed to create therapeutic antibodies. The company focuses on hard-to-target proteins, such as G-protein coupled receptors (GPCRs) and ion channels. These proteins play critical roles in various conditions, including cancer, neurological disorders, and rare genetic diseases like cystic fibrosis.
The company employs a unique blend of machine learning and laboratory validation to generate and evaluate antibody candidates. Its models are dedicated to designing antibodies that target specific disease-related proteins, which are then synthesized and tested using proprietary cell systems that mimic the physiological conditions of the human body. This dual approach ensures that only the most promising candidates advance toward clinical development.
Collaboration with the Cystic Fibrosis Foundation
As part of its commitment to tackling complex medical challenges, Antiverse has established a research agreement with the Cystic Fibrosis Foundation. This collaboration focuses on developing antibodies aimed at the extracellular region of the CFTR protein—a notoriously difficult target. By leveraging its AI-driven platform, Antiverse aims to expedite the evaluation of innovative therapeutic strategies.
Streamlining Discovery Processes
Antiverse’s integrated approach marries AI-driven design with robust experimental validation, enhancing the efficiency of antibody discovery for complex disease targets. This synergy allows for rapid iterations between computational design and laboratory testing, significantly reducing the time required to identify viable therapeutic candidates.
Future Growth and Initiatives
The newly acquired funding will empower Antiverse to expand its AI-powered antibody discovery platform. The company plans to collaborate with pharmaceutical partners and foundations to develop new therapeutic programs. Additionally, the investment will support the growth of Antiverse’s internal drug pipeline, advancing lead antibody programs toward in vivo efficacy studies.
The Path Ahead
Antiverse’s innovative strategies position the company at the forefront of the biotech industry, where the intersection of AI and biology offers unprecedented opportunities. With the potential to revolutionize the treatment of challenging diseases, the company’s efforts reflect a modern approach to drug discovery that could change countless lives.
In conclusion, Antiverse’s recent funding achievement marks a significant milestone in its journey to reshape the landscape of antibody discovery. By harnessing advanced technology and fostering strategic partnerships, the company is poised to make impactful strides in addressing some of the most challenging medical targets. The future of targeted therapies looks promising with Antiverse leading the charge.
- Antiverse raised $9.3 million in Series A funding.
- The company focuses on developing antibodies for hard-to-target diseases.
- Collaboration with the Cystic Fibrosis Foundation aims to tackle difficult targets.
- Antiverse’s approach combines AI design with laboratory validation for efficiency.
- The funding will enhance partnerships and expand internal drug development.
Read more → tech.eu